e-learning
resources
Virtual 2020
Pre-Congress Content
Localised non-small cell lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Characteristics and survival analysis of synchronous oligometastatic non-small cell lung carcinoma.
G. Cintrão Samouco (Guarda, Portugal), T. Almodôvar (Lisboa, Portugal), J. Duro Da Costa (Lisboa, Portugal)
Source:
Virtual Congress 2020 – Localised non-small cell lung cancer
Session:
Localised non-small cell lung cancer
Session type:
E-poster session
Number:
1629
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Cintrão Samouco (Guarda, Portugal), T. Almodôvar (Lisboa, Portugal), J. Duro Da Costa (Lisboa, Portugal). Characteristics and survival analysis of synchronous oligometastatic non-small cell lung carcinoma.. 1629
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Related content which might interest you:
Survival and prognostic factors of oligometastatic non-small cell lung carcinoma: A single center experience
Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Year: 2017
Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment
Source: Annual Congress 2006 - Prognostic factors in lung cancer
Year: 2006
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Does long treatment delay affect survival in metastatic non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
How to treat a T1-T3N0 non-small cell lung cancer (NSCLC) with isolated brain metastasis
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Features of N-staging in left-sided non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 719s
Year: 2006
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Year: 2011
Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
Analysis of risk factors for brain metastasis in locally advanced stage non-small cell carcinoma
Source: Annual Congress 2010 - Best supportive care and palliation for lung cancer patients
Year: 2010
Role of chemokines in resectable non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Management of brain metastases in patients with non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Early recurrence in complete resected non-small cell lung cancer patients
Source: International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Year: 2017
How to handle oligometastatic disease in nonsmall cell lung cancer
Source: Eur Respir Rev, 30 (159) 200234; 10.1183/16000617.0234-2020
Year: 2021
Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
Source: Eur Respir Rev 2015; 25: 65-70
Year: 2016
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
Prognostic factors for unresectable non-small cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 270s
Year: 2002
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient
Source: Eur Respir J 2015; 46: 280-282
Year: 2015
How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations
Source: International Congress 2015 – How to treat brain metastases
Year: 2015
Clinical characterization of non-small cell lung cancer tumors showing neuroendocrine differentiation
Source: Eur Respir J 2002; 20: Suppl. 38, 270s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept